Summarize the recent developments in medical treatments and therapies.

Several recent advances are changing how clinicians treat chronic disease, cancer, and some inherited conditions. The most notable shift is toward treatments tailored to a specific disease pathway or patient group, though many newer options remain costly, specialized, or suitable only for certain people.

Notable developments

• GLP-1 medicines for obesity: Drugs such as semaglutide and tirzepatide have expanded beyond diabetes care. Evidence has strengthened for weight management and, for some patients, reduced risks linked to cardiovascular disease. Research and approvals continue to develop, and these medicines are not appropriate for everyone.
• CRISPR-based treatment for sickle cell: The first CRISPR gene-editing treatments received regulatory approvals beginning in 2023. They can offer a one-time treatment option for some people with severe blood disorders, but require intensive care and are not widely accessible.
• New Alzheimer’s drugs: Lecanemab and donanemab can modestly slow cognitive decline in some people with early Alzheimer’s disease. They do not reverse the condition, and treatment involves careful monitoring for brain swelling or bleeding.
• More targeted cancer therapies: Antibody-drug conjugates and bispecific antibodies have added options for particular cancers. They deliver treatment to selected targets or help immune cells recognize cancer, but eligibility depends on the cancer type and its molecular features. Cell therapies such as CAR-T are also being used for a growing range of blood cancers.
• RSV vaccines and preventive antibodies: New prevention options for respiratory syncytial virus became available for older adults, infants, and, in some settings, pregnant people. Which option is recommended depends on age, health, and local guidance.

These examples are not a complete list, and availability varies by country. A treatment’s approval does not mean it is suitable for every patient; clinicians weigh expected benefits, side effects, cost, and alternatives.